Literature DB >> 14959779

The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohort.

F Tyrer1, A S Walker, J Gillett, K Porter.   

Abstract

Seroconversion illness is known to be associated with more rapid HIV disease progression. However, symptoms are often subjective and prone to recall bias. We describe symptoms reported as seroconversion illness and examine the relationship between illness, HIV test interval (time between antibody-negative and anibody-positive test dates) and the effect of both on time to AIDS from seroconversion. We used a Cox model, adjusting for age, sex, exposure group and year of estimated seroconversion. Of 1820 individuals, information on seroconversion illness was available for 1244 of whom 423 (34%) reported symptomatic seroconversion. Persons with a short test interval (< or = 2 months) were significantly more likely to report an illness than people with a longer interval (OR 6.76, 95% CI 4.75-9.62). Time to AIDS was significantly faster (P = 0.01) in those with a short test interval. The HIV test interval is a useful replacement for information on seroconversion illness in studies of HIV disease progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14959779      PMCID: PMC2870061          DOI: 10.1017/s0950268803001377

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  3 in total

1.  Prevalence of seroconversion symptoms and relationship to set-point viral load: findings from a subtype C epidemic, 1995-2009.

Authors:  Patrick S Sullivan; Ulgen Fideli; Kristin M Wall; Elwyn Chomba; Cheswa Vwalika; William Kilembe; Amanda Tichacek; Nicole Luisi; Joseph Mulenga; Eric Hunter; Debrah Boeras; Susan Allen
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

2.  The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort.

Authors:  Mathias Altmann; Matthias An der Heiden; Ramona Scheufele; Katrin Hartmann; Claudia Houareau; Barbara Bartmeyer; Osamah Hamouda
Journal:  BMC Infect Dis       Date:  2012-04-19       Impact factor: 3.090

3.  Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy.

Authors:  Jim Todd; Judith R Glynn; Milly Marston; Tom Lutalo; Sam Biraro; Wambura Mwita; Vinai Suriyanon; Ram Rangsin; Kenrad E Nelson; Pam Sonnenberg; Dan Fitzgerald; Etienne Karita; Basia Zaba
Journal:  AIDS       Date:  2007-11       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.